Treatments

Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes

Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes

By

A study of the once-weekly investigational dipeptidyl peptidase-4 omarigliptin reported a clinically meaningful reduction in glycated hemoglobin that was maintained throughout the study.

Statin Use for CVD Prevention Increases Diabetes Risk in Overweight Patients

Statin Use for CVD Prevention Increases Diabetes Risk in Overweight Patients

By

The association between statin use and diabetes risk in a cohort of overweight and obese patients was examined.

Short-Term Probiotics Increase Weight Loss in Overweight, Obesity

Short-Term Probiotics Increase Weight Loss in Overweight, Obesity

Probiotic supplementation resulted in a significant reduction in body weight, BMI, and fat percentage in people with overweight or obesity.

Insulin Glargine Associated With Breast Cancer Risk in T2D

Insulin Glargine Associated With Breast Cancer Risk in T2D

By

Researchers assessed whether long-term use of long-acting insulin analogs, compared with the use of neutral protamine Hagedorn insulin, is associated with an increased risk of breast cancer in women with T2D.

FDA Approves Drug for Mucopolysaccharidosis Type VII

FDA Approves Drug for Mucopolysaccharidosis Type VII

By

Mepsevii replaces beta-glucuronidase, the deficiency of which causes an abnormal buildup of toxic materials in the body's cells.

Dementia Risk Reduced With Metformin in Veterans With T2D

Dementia Risk Reduced With Metformin in Veterans With T2D

Metformin is linked to a lower dementia risk compared to sulfonylureas among veterans with type 2 diabetes.

Patient Nonadherence Often Misidentified as Diabetes Treatment Failure

Patient Nonadherence Often Misidentified as Diabetes Treatment Failure

Second-line treatments are often initiated without first using first-line therapies.

DPP4-i Plus α-Glucosidase Inhibitor Reduces HbA1c in T2D

DPP4-i Plus α-Glucosidase Inhibitor Reduces HbA1c in T2D

People with T2D experienced greater HbA1c reductions with the addition of a DPP4 inhibitor vs placebo.

FDA Approves Exenatide Extended-Release Injection for T2D

FDA Approves Exenatide Extended-Release Injection for T2D

By

The new formulation of Bydureon BCise allows for once-weekly administration with an autoinjector pen.

Improved Outcomes in Prediabetes, T2D With Liraglutide

Improved Outcomes in Prediabetes, T2D With Liraglutide

The efficacy of liraglutide therapy was examined in metformin-treated subjects with obesity.

High-Dose Beta-Blockers More Effective in Chronic Heart Failure, Diabetes

High-Dose Beta-Blockers More Effective in Chronic Heart Failure, Diabetes

By

Greater prognostic advantages were associated with high-dose beta blockers in chronic heart failure with diabetes.

Treating Endometriosis-Related Pain With Ethinylestradiol/Drospirenone Regimen

Treating Endometriosis-Related Pain With Ethinylestradiol/Drospirenone Regimen

Researchers examined the efficacy of FlexibleMIB (ethinylestradiol/drospirenone) vs placebo as therapy for endometriosis-related pain.

T2D Therapies: Tofogliflozin Efficacy With High Baseline Insulin

T2D Therapies: Tofogliflozin Efficacy With High Baseline Insulin

HbA1c, fasting plasma glucose, and body weight were significantly reduced in all patients taking tofogliflozin.

Heart Failure Outcomes: Worse Long-Term Prognosis in Diabetes

Heart Failure Outcomes: Worse Long-Term Prognosis in Diabetes

Ten-year heart failure outcomes were worse in patients with diabetes than without.

VA, DoD Release New T2D Clinical Practice Guideline

VA, DoD Release New T2D Clinical Practice Guideline

The update provides guidance within 7 areas of type 2 diabetes management, including patient centered care and individualized treatment plans.

ADA Position Statement Update: Hypertension Management in Diabetes

ADA Position Statement Update: Hypertension Management in Diabetes

By

The latest ADA hypertension position statement incorporates advances in care since 2003.

Evolocumab May Decrease Cardiovascular Risk in Patients With and Without Diabetes

Evolocumab May Decrease Cardiovascular Risk in Patients With and Without Diabetes

By

PCSK9 inhibition with evolocumab might be an attractive therapy in patients with diabetes, and no discernible effect on glycaemia.

Insulin Plus Sulfonylurea, Metformin Linked to HbA1c Reduction

Insulin Plus Sulfonylurea, Metformin Linked to HbA1c Reduction

However, sulfonylurea plus insulin was linked to more hypglycemic events than insulin alone.

Following Approval, Triptorelin 6-Month Injection Now Available to Treat Central Precocious Puberty

Following Approval, Triptorelin 6-Month Injection Now Available to Treat Central Precocious Puberty

By

Gonadotropin-releasing hormone (GnRH) agonist Triptodur treats central precocious puberty via intramuscular injection.

Diabetes Self-Management Class Participation Varies in Adults with T2D

Diabetes Self-Management Class Participation Varies in Adults with T2D

Clinicians should identify barriers to patient participation in diabetes self-management classes.

Efficacy of Hyperbaric Oxygen Therapy in Diabetic Foot Ulcers

Efficacy of Hyperbaric Oxygen Therapy in Diabetic Foot Ulcers

By

The efficacy and safety profile of hyperbaric oxygen therapy remains controversial because of conflicting data and small sample sizes in clinical trials.

Managing Menopausal Symptoms in Breast Cancer Survivors

Managing Menopausal Symptoms in Breast Cancer Survivors

By

Lifestyle modification and an individualized treatment approach are effective strategies for managing menopausal symptoms in breast cancer survivors who are largely advised to avoid hormone replacement therapy.

Peptide Immunotherapy for Type 1 Diabetes: A Promising New Treatment

Peptide Immunotherapy for Type 1 Diabetes: A Promising New Treatment

By

Peptide immunotherapy may offer a personalized approach to modulating the immune response in persons with type 1 diabetes.

Availability of Insulin Lispro Injection to Treat Diabetes

Availability of Insulin Lispro Injection to Treat Diabetes

By

Approved in June 2017, the Humalog Junior KwikPen will soon be available to treat patients with diabetes.

Reducing HbA1c in T2D: Efficacy of Immune-Modulator Anti-Inflammatory Treatments

Reducing HbA1c in T2D: Efficacy of Immune-Modulator Anti-Inflammatory Treatments

Diacerein was well-tolerated among trial participants, and may be an acceptable adjunct treatment in type 2 diabetes.

Counseling vs Standard Care to Increase Physical Activity in T2D

Counseling vs Standard Care to Increase Physical Activity in T2D

Three hundred physically inactive or sedentary patients received either theoretical and practical counseling once-yearly for 3 years, or standard care.

Glycemic Control in Physically Active Adolescents With T1D: Closed-Loop Control vs Remote Pump in Winter Sports

Glycemic Control in Physically Active Adolescents With T1D: Closed-Loop Control vs Remote Pump in Winter Sports

During a 5-day ski camp, researchers examined closed-loop insulin management vs a remote monitored pump system for glycemic control with the additional challenge of cold and altitude.

Endocrine Treatment in Transgender Individuals: Guidelines in Brief

Endocrine Treatment in Transgender Individuals: Guidelines in Brief

By

The newly released guidelines include updated language to reflect DSM-V changes, greater flexibility in treatment, and recommendations for CVD, bone health, and prostate cancer screening.

Pain Perception in Adrenal Insufficiency Not Affected by Hydrocortisone Dose

Pain Perception in Adrenal Insufficiency Not Affected by Hydrocortisone Dose

By

Mechanical pain perception and somatosensory function in secondary adrenal insufficiency were examined.

Lowering Heart Failure Hospitalizations in T2D: SGLT2 vs DPP4 Inhibitors

Lowering Heart Failure Hospitalizations in T2D: SGLT2 vs DPP4 Inhibitors

By

A retrospective analysis examined outcomes in patients with type 2 diabetes treated with SGLT2 vs DPP4 inhibitors.

Sign Up for Free e-Newsletters

CME Focus